Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio. It also offers cardiovascular products, consisting of several cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for various treatments to control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. In addition, the company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. The company sells its products primarily to drug wholesalers and retailers, hospitals, and government agencies, as well as managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was incorporated in 2020 and is based in Jersey City, New Jersey.
Organon & Dividend Announcement
• Organon & announced a quarterly dividend of $0.28 per ordinary share which will be made payable on 2024-12-12. Ex dividend date: 2024-11-12
• Organon & annual dividend for 2024 was $1.12
• Organon & annual dividend for 2023 was $1.12
• Organon &'s trailing twelve-month (TTM) dividend yield is 7.41%
• Organon &'s payout ratio for the trailing twelve months (TTM) is 22.75%
Organon & Dividend History
Ex-Div date | Dividend amount | Dividend type | Pay date |
---|---|---|---|
2024-11-12 | $0.28 | quarterly | 2024-12-12 |
2024-08-16 | $0.28 | quarterly | 2024-09-12 |
2024-05-10 | $0.28 | quarterly | 2024-06-13 |
2024-02-23 | $0.28 | quarterly | 2024-03-14 |
2023-11-10 | $0.28 | quarterly | 2023-12-14 |
2023-08-17 | $0.28 | quarterly | 2023-09-14 |
2023-05-12 | $0.28 | quarterly | 2023-06-15 |
2023-02-24 | $0.28 | quarterly | 2023-03-16 |
2022-11-10 | $0.28 | quarterly | 2022-12-15 |
2022-08-12 | $0.28 | quarterly | 2022-09-15 |
2022-05-13 | $0.28 | quarterly | 2022-06-16 |
2022-02-25 | $0.28 | quarterly | 2022-03-17 |
2021-11-19 | $0.28 | quarterly | 2021-12-16 |
2021-08-20 | $0.28 | quarterly | 2021-09-13 |
Organon & Dividend per year
Organon & Dividend growth
Organon & Dividend Yield
Organon & current trailing twelve-month (TTM) dividend yield is 7.41%. Interested in purchasing Organon & stock? Use our calculator to estimate your expected dividend yield:
Organon & Financial Ratios
Organon & Dividend FAQ
Other factors to consider when evaluating Organon & as a dividend stock include its dividend yield, dividend growth, payout ratio, and the sustainability of its dividend payments given its earnings and cash flow. These factors can provide insight into the company's ability to maintain or increase its dividend in the future.
Place an order: Use the brokerage's trading platform to place an order to buy Organon & stock.
Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.
1. Determination of Dividend: Organon &'s board of directors reviews the company's financial performance, cash flow, future investment needs, and other relevant factors to determine the amount and timing of dividend payments.
2. Dividend Declaration: Once the board approves a dividend, Organon & publicly announces the dividend amount, currency, and the ex-dividend date. The ex-dividend date is the date on or after which the buyer of the stock will not be eligible to receive the upcoming dividend payment.
3. Record Date: The record date is the date on which the company checks its records to identify shareholders who are eligible to receive the dividend. Only shareholders on record as of this date will receive the dividend.
4. Payment Date: On the designated payment date, Organon & distributes the dividend to eligible shareholders. The dividend is usually paid in the form of cash directly into the shareholder's brokerage account or through other designated payment methods.
5. Tax Implications: Dividends received from Organon & are generally taxable as income. Shareholders may need to report dividend income on their tax returns and pay applicable taxes according to their jurisdiction's tax regulations.
1. Record Date: Organon & sets a record date, which is the date on which the company checks its records to determine the eligible shareholders. Only those who are shareholders on record as of this date will receive the dividend.
2. Payment Date: On the designated payment date, Organon & distributes the dividend to eligible shareholders. The payment is usually made electronically, directly into the shareholder's brokerage account or bank account.
3. Currency: Organon & declares the currency in which the dividend will be paid. Depending on the shareholder's location and the currency election made by the shareholder, the dividend will be converted to the appropriate currency during the payment process.
To assess the safety of Organon &'s dividend, it is crucial to analyze the company's financial health, debt levels, cash flow generation, and ability to sustain dividend payments over the long term. Additionally, monitoring the company's future earnings, cash flow projections, and management's commitment to dividend policies can provide valuable insights.
It is recommended to review Organon &'s financial reports, official announcements, and consult with financial advisors or experts who have access to the most current and comprehensive information about the company's financial situation.